Yarbrough Capital’s Neurocrine Biosciences NBIX Stock Holding History

Yarbrough Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,714	Closed	-$205K	–	222
2022 Q4	$205K	Sell	1,714 -1,082	-39%	-$127K	0.02%	166
2022 Q3	$297K	Hold	2,796	–	–	0.02%	159
2022 Q2	$273K	Sell	2,796 -807	-22%	-$74.5K	0.02%	158
2022 Q1	$338K	Buy	3,603 +807	+29%	+$68.4K	0.02%	179
2021 Q4	$238K	Buy	+2,796	New	+$257K	0.01%	206

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Yarbrough Capital's NBIX Position: Q1 2023 in Review

Yarbrough Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 1,714 shares — an estimated $205K sold.

Yarbrough Capital first reported a position in NBIX in Q4 2021 and held it in 5 quarters. The position peaked at $338K in Q1 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

Yarbrough Capital reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
Yarbrough Capital sold 1,714 Neurocrine Biosciences shares in Q1 2023, an estimated $205K.
Yarbrough Capital first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 5 quarters.
Yarbrough Capital's Neurocrine Biosciences position peaked at $338K in Q1 2022.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Yarbrough Capital's 13F filing for Q1 2023, filed 13 Apr 2023.